

**Supplementary Table:****Supplementary Table S1: Characteristics of eight AMKL patients with t(1;22)(p13;q13)**

Patient	Age (y)	Sex	Karyotype	Therapy	Outcome
#1	0.12	m	46,XY,t(1;22)(p13;q13)[8]	AML-BFM 98	Death in CCR after MUD HSCT
#2	0.24	f	46,XX,t(1;22)(p13;q13)[13]	AML-BFM 04	CCR after MUD HSCT in NR
#3	0.59	f	no karyotype, t(1;22)(p13;q13) in FISH	AML-BFM 04	Early Death
#4	0.30	f	46,XX,inv(7)(q21q33)[18]; 46,idem,t(1;22)(p31;q12)[2]	AML-BFM 04	CCR after MRD HSCT in NR
#5	1.19	m	49,XY,t(1;22)(p13;q13),+2,der(2)(p),+8,+19[cp11]	AML-BFM 04	CR
#6	1.52	f	no karyotype, t(1;22)(p13;q13) in FISH	AML-BFM 04	Early Death
#7	0.25	m	50~55,t(1;22)(p13;q13),inc	AML-BFM 98	CR
#8	6.26	m	68~69,XXYY,der(1)t(1;22)(p13;q13),-1,-2,-4,-4,-5,-5,-6,-7,-9,-9,-11,-12,-12,-13,-14,-15,-15,-16,-17,-18,-18,-20,-20,-22,+mar[cp5]	AML-BFM 98	Death in CCR